Ifn-β_1B Treatment of Relapsingmultiple Sclerosis Has no Effect on Cd3-Induced Inflammatory or Counterregulatory Anti-Inflammatory Cytokine Secretion Ex Vivo After Nine Months

References

• Arnason B., Jensen M., Lledo A., Dayal A. Interferon γ (IFN-γ)-secreting cells in multiple sclerosis (MS) treated with interferon β1b. Neurology 1995; 45: 2173–2177
   PubMed Web of Science ®Google Scholar
• Antel J. P., Freedman M. S., Brodsovsky S., Francis G. S., Duquette P. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Annals of Neurology 1989; 25: 204–207
   PubMed Web of Science ®Google Scholar
• Balkwill F. R. The regulatory role of interferons in the human immune response. Interferons: Their impact in biology of medicine, J. Taylor-Papadimitriou. Oxford Medical Publications, OxfordUK 1985; 61–80
   Google Scholar
• Baxevanis C. N., Reclos G. J., Ansenis P., Anastasopoulaos E., Katsiyiannis A., Lymberi P., Mitikas N., Papamichail M. Decreased expression of HLA-Dr antigens on monocytes in patients with MS. Journal of Neuroimmunology 1989; 22: 177–183
   PubMed Web of Science ®Google Scholar
• Baxevanis C. N., Reclos G. J., Papamichail M. Decreased HLA-Dr antigen expression in monocytes causes impaired suppressor cell activity in multiple sclerosis. Journal of Neuroimmunology 1990; 27: 4166–4171
   Google Scholar
• Bettens S., Walker C., Gauchat J.-F., Gauchat D., Wyss T., Pichler W. J. Lymphokine gene expression related to CD4 T cell subset CD45R/CDw29) phenotype conversion. European Journal of Immunology 1987; 19: 1569–1574
   Web of Science ®Google Scholar
• Bottomly K., Luqman M., Greenbaum L., Carding S., West J., Pasqualini H., Murphy D. B. A monoclonal antibody to murine CD45R distinguishes CD4 T cell populations that produce different cytokines. European Journal of Immunology 1989; 19: 617–623
   PubMed Web of Science ®Google Scholar
• Brod S. A., Khan M., Marshall G. D., Henninger E. M., Wolinsky J. S. IFN-β-1b [Betaseron] treatment of relapsing-remitting multiple sclerosis decreases CD3-mediated TNF-α and increases CD3-mediated IL-6 production in vitro. Neurology 1996; 46: 1633–1638
   PubMed Web of Science ®Google Scholar
• Budd R. C., Cerottinini J. C., MacDonald H. R. Selectively increased production of IFN-γ by subsets of Lyt-2+ and L3T4+ T cells identified by expression of Pgp-1. Journal of Immunology 1987; 138: 3583–3586
   PubMed Web of Science ®Google Scholar
• Byrne J. A., Butler J. L., Cooper M. D. Differential activation requirements for virgin and memory T cells. Journal of Immunology 1988; 141: 3249–3257
   PubMed Web of Science ®Google Scholar
• Durelli L., Bongioanni M. R., Cavallo R., Ferraro B., Ferri R., Ferrio M. F., Bradac G. B., Riva A. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate. MRI signs of activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406–413
   PubMed Web of Science ®Google Scholar
• Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon-β/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences (USA) 1987; 84: 7251–7255
   PubMed Web of Science ®Google Scholar
• IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662–667
   PubMed Web of Science ®Google Scholar
• IFNB MS Study Group. Interferon-beta lb is effective in relapsing-remitting multiple sclerosis, I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 655–661
   PubMed Web of Science ®Google Scholar
• IFNB MS Study Group. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–1285
   PubMed Web of Science ®Google Scholar
• Horgan K. J., Seventer G. A. V., Shimizu Y., Shaw S. Hyporesonsiveness of “naive” (CD45RA+) human T cells to multiple receptor mediated stimuli but augmentation of responses by co-stimuli. European Journal of Immunology 1990; 20: 1111–1120
   PubMed Web of Science ®Google Scholar
• Jacobs L., Cookfair D., Rudick R., Herndon R., Richert J., Salazar A., Fischer J., Granger C. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Annals of Neurology 1994; 36(2)259
   Web of Science ®Google Scholar
• Koulova L., Yang S. Y., Dupont B. Identification of the anti-CD3-unresponsive sub-population of CD4+CD45RA+ peripheral T lymphocytes. Journal of Immunology 1990; 145: 2035–2043
   PubMed Web of Science ®Google Scholar
• Morimoto C., Letvin N. L., Diastaso J. A., Aldrich W. R., Sclossman S. F. The isolation and characterization of the human suppressor inducer T cell subset. Journal of Immunology 1985; 134: 1508–1512
   PubMed Web of Science ®Google Scholar
• Morimoto C., Letvin N. L., Rudd C. E., Hagan M., Takeuchi T., Sciossman S. F. The role of the 2H4 molecule in the generation of suppressor function in Con A-activated T cells. Journal of Immunology 1986; 137: 3247–3253
   PubMed Web of Science ®Google Scholar
• Noronha A., Toscas A., Jensen M. A. IFN-β decreases T cell activation and IFN-γ production in multiple sclerosis. Journal of Neuroimmunology 1993; 46: 145–154
   PubMed Web of Science ®Google Scholar
• Porrini A., Gambi D., Reder A. Interferon effects on IL-10 secretion—mononuclear cell response to IL-10 is normal in multiple sclerosis patients. Journal of Neuroimmunology 1995; 61: 27–34
   PubMed Web of Science ®Google Scholar
• Poser C. M., Paty D. W., Scheinberg L., MaDonald W., Davis F., Ebers G., Johnson K., Sibley W. New diagnostic criteria for multiple sclerosis. Annals of Neurology 1983; 13: 227–231
   PubMed Web of Science ®Google Scholar
• Powrie F., Correa-Olivirera R., Mauze S., Coffman R. Regulatory interactions between CD45RBhigh and CD45RBfow CD4+ T cells are important for a balance between protective and pathogenic cell-mediated immunity. Journal of Experimental Medicine 1994; 179: 589–600
   PubMed Web of Science ®Google Scholar
• Quality Standards Committee. A. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994; 44: 1537–1539
   PubMed Web of Science ®Google Scholar
• Robinson A. T., Miller N., Alexander D. R. CD3 antigen-mediated calcium signals and protein kinase C activation are higher in CD45RO+ than in CD45RA+ human T lymphocyte subsets. European Journal of Immunology 1993; 23: 61–68
   PubMed Web of Science ®Google Scholar
• Rudick R. A., Carpenter C. S., Cookfair D. L., Tuohy V. K., Ransahoff R. M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-beta. Neurology 1993; 43: 2080–2087
   PubMed Web of Science ®Google Scholar
• Salmon M., Kitas G. D., Bacon P. A. Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones. Journal of Immunology 1989; 143: 907–912
   PubMed Web of Science ®Google Scholar
• Sanders M. E., Makgoba M. W., June C. H., Young H. A., Shaw S. Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor mediated activation. European Journal of Immunology 1989; 19: 803–808
   PubMed Web of Science ®Google Scholar
• Spear G. T., Paulnock D. M, Jordan R. L. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo b interferon. Clinical and Experimental Immunology 1987; 69: 107–115
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttmann B., Ransahoff R. M., Kinkel R. P., Rudick R. A. The Interferons: biological effects, mechanism of action and use in multiple sclerosis. Annals of Neurology 1995; 37: 7–15
   PubMed Web of Science ®Google Scholar
• Wolinsky J. Multiple Sclerosis. Current Neurology, S. A. Appel, 1993; vol. 13: 167–207
   Google Scholar